A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The combination of lenalidomide plus low-dose dexamethasone (Rd) is considered the new
standard for elderly newly diagnosed multiple myeloma (NDMM) patients. The combination
carfilzomib plus lenalidomide-dexamethasone (KRd) in relapsed-refractory MM patients improved
the progression-free survival (PFS) of approximately 1 year compared to standard Rd
treatment. In a small phase 2 trial (23 pts) the KRd combination in elderly NDMM pts showed a
complete response (CR) rate of 79% and a PFS at 3 years of 80%. Cardiovascular adverse events
are the most limiting toxicities, especially in elderly patients.